about
Severe asthma: anti-IgE or anti-IL-5?Genotype-dependent effects of TGF-β1 on mast cell function: targeting the Stat5 pathwayRagweed-induced allergic rhinoconjunctivitis: current and emerging treatment options.Anaphylaxis: mechanisms and management.The Leaves of Broussonetia kazinoki Siebold Inhibit Atopic Dermatitis-Like Response on Mite Allergen-Treated Nc/Nga Mice.A comparative pilot study of symptom improvement before and after phototherapy in Korean patients with perennial allergic rhinitis.Janus kinase-3 dependent inflammatory responses in allergic asthmaPrevention of anaphylaxis related to mast cell activation syndrome with omalizumabA review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthmaNew approaches to managing asthma: a US perspectiveDevelopment of an antibody that neutralizes soluble IgE and eliminates IgE expressing B cells.The mast cell and allergic diseases: role in pathogenesis and implications for therapy.Chronic urticaria: the autoimmune paradigm.IgE and mast cells in allergic disease.An overview of the effects of anti-IgE therapies.The Use of Omalizumab in Food Oral Immunotherapy.Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.Insights in Anaphylaxis and Clonal Mast Cell Disorders.Cytomegalic hepatitis in a patient receiving omalizumab.Severe asthma and the omalizumab option.Advances in anti-IgE therapyRifampicin Alleviates Atopic Dermatitis-Like Response in vivo and in vitro.Effects of omalizumab on eosinophil cationic peptide, 25-hydroxyvitamin-D, IL-1β and sCD200 in cases of Samter's syndrome: 36 months follow-up.Omalizumab is effective in treating severe asthma in patients with severe cardiovascular complications and its effects on sCD200, d-dimer, CXCL8, 25-hydroxyvitamin D and IL-1β levels.Omalizumab for difficult-to-treat dermatological conditions: clinical and immunological features from a retrospective real-life experience.DW2008S and its major constituents from Justicia procumbens exert anti-asthmatic effect via multitargeting activity.Type 2 immunity in asthma.
P2860
Q28071832-B8F5CE57-E96F-4A20-BAA3-CDD8937A59E2Q28587516-170F2827-0FE1-4CAD-8A35-46CF29E56B62Q30903098-CEE06B5E-2ECF-40E5-BAEF-2CF7CCF5BA0AQ34192100-B6DF4784-62B3-40ED-8DEB-4918D45DB5BEQ34360558-B06AAFEA-CAF3-40D1-B2AC-73258A8927E9Q34517986-B31AE996-0717-42D3-B0D7-E9F67D4FAC04Q35031161-6C246984-4758-47B1-95DC-B4C0FF2113F6Q35923472-AC759FA5-7C34-41AD-9312-3C97ECE64DD7Q36642971-EAF43827-CE37-4913-B191-C143507FE172Q36823534-BEAF71F8-7A5A-44E0-AC74-A525CB1541CCQ36870059-7A1E5298-414D-4B5C-8BE3-9919EF99239AQ37010493-3C7D3895-BEE9-43E0-BD7F-849C3A33A759Q37361510-BA6353C0-59C1-4916-8535-ADFDA7E445F0Q38007829-B66D58E8-B32C-4F6F-934B-383D912BCDEBQ38252958-37E640B7-6AFE-4BFA-93E3-54C6D94DB544Q38954322-FBC88525-8E76-4E96-AB8D-1AF40D2A4228Q39012896-E33285C4-D81B-44C2-B200-45277D8FB6EAQ39455752-CA653C81-D9E2-4A9F-A2F9-5F5FF7C7AA5BQ40555356-A2EBA2C6-D119-4CE3-897B-A8E3DD8E59B5Q40740336-9642607F-CADA-45FB-9051-A7D7577A4E73Q40812061-5F69CDAF-4C0C-4AEC-8F54-290D2AA101CBQ44074770-D62A2073-1431-48C3-B4DA-FE1D91E686E1Q44528029-D605D832-851B-402B-9096-5417B8A708EBQ47943679-20E12009-310D-41E5-9D5A-0131FAE4A7FBQ52976551-50503147-5F07-4229-A9B0-04EE054D2FA6Q54993007-C8488FF8-0703-4C5C-BFBC-5D8A37203BA6Q55454410-C09D9147-CE00-440B-B5E6-2BE0699A64E3
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Anti-IgE as a mast cell-stabilizing therapeutic agent.
@ast
Anti-IgE as a mast cell-stabilizing therapeutic agent.
@en
Anti-IgE as a mast cell-stabilizing therapeutic agent.
@nl
type
label
Anti-IgE as a mast cell-stabilizing therapeutic agent.
@ast
Anti-IgE as a mast cell-stabilizing therapeutic agent.
@en
Anti-IgE as a mast cell-stabilizing therapeutic agent.
@nl
prefLabel
Anti-IgE as a mast cell-stabilizing therapeutic agent.
@ast
Anti-IgE as a mast cell-stabilizing therapeutic agent.
@en
Anti-IgE as a mast cell-stabilizing therapeutic agent.
@nl
P1476
Anti-IgE as a mast cell-stabilizing therapeutic agent.
@en
P2093
Tse Wen Chang
Yu-Yu Shiung
P304
1203-12; quiz 1213
P356
10.1016/J.JACI.2006.04.005
P407
P577
2006-05-11T00:00:00Z